2023
Prevalence of injecting drug use and HIV, hepatitis B, and hepatitis C in people who inject drugs in the Eastern Mediterranean region: a systematic review and meta-analysis
Aghaei A, Gholami J, Sangchooli A, Rostam-Abadi Y, Olamazadeh S, Ardeshir M, Baheshmat S, Shadloo B, Taj M, Saeed K, Rahimi-Movaghar A. Prevalence of injecting drug use and HIV, hepatitis B, and hepatitis C in people who inject drugs in the Eastern Mediterranean region: a systematic review and meta-analysis. The Lancet Global Health 2023, 11: e1225-e1237. PMID: 37474230, DOI: 10.1016/s2214-109x(23)00267-x.Peer-Reviewed Original ResearchConceptsPrevalence of injection drug useInjection drug usePrevalence of HIVHepatitis B virusHepatitis C virusB virusC virusMeta-analysisSystematic reviewHepatitis C virus infection ratesEastern Mediterranean RegionCharacteristics of peopleDrug useHIV infection ratesOpioid agonist treatmentInfection rateProgramme servicesPopulation size of peopleHepatitis CAgonist treatmentHarm reduction servicesHepatitis BWHO Eastern Mediterranean RegionWeb of ScienceProvision of services
2021
HIV prevalence among non‐injecting people who use drugs and related factors in Iran: A systematic review and meta‐analysis
Gholami J, Rostam‐Abadi Y, Rahimi Y, Fotouhi A, Amin‐Esmaeili M, Rahimi‐Movaghar A. HIV prevalence among non‐injecting people who use drugs and related factors in Iran: A systematic review and meta‐analysis. Drug And Alcohol Review 2021, 41: 666-676. PMID: 34783411, DOI: 10.1111/dar.13407.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus prevalenceHuman immunodeficiency virusOdds of HIV infectionHIV infectionSystematic reviewPrevalence of human immunodeficiency virusPrevalence of HIV infectionReduce HIV prevalenceRandom-effects modelCitation trackingHIV prevalenceImmunodeficiency virusNo significant differenceHarm reductionPWUDGeneral populationUnpublished studiesGender subgroupsComprehensive searchNational databaseMeta-analysisSignificant differencePrevalencePreventive measuresInfection
2020
Hepatitis B virus infection among people who use drugs in Iran: a systematic review, meta-analysis, and trend analysis
Rostam-Abadi Y, Rafiemanesh H, Gholami J, Shadloo B, Amin-Esmaeili M, Rahimi-Movaghar A. Hepatitis B virus infection among people who use drugs in Iran: a systematic review, meta-analysis, and trend analysis. Harm Reduction Journal 2020, 17: 81. PMID: 33087141, PMCID: PMC7579800, DOI: 10.1186/s12954-020-00424-w.Peer-Reviewed Original ResearchConceptsHepatitis B virusHepatitis B virus infectionPrevalence of HBV infectionHepatitis B virus prevalenceHBV infectionSubgroups of PWIDHepatitis B virus surface antigenB virus infectionRandom-effects model meta-analysisMeta-analysisPrevalence of HBsAgEstimation of HBsAgHigh-risk groupSystematic reviewPooled prevalence of HBsAgHarm reduction interventionsMeta-regression analysisPositive HBsAgHistory of imprisonmentHBsAg prevalenceB virusConclusionThe prevalenceReduction interventionsAt-risk populationsHBsAgTramadol use and public health consequences in Iran: a systematic review and meta‐analysis
Rostam‐Abadi Y, Gholami J, Amin‐Esmaeili M, Safarcherati A, Mojtabai R, Ghadirzadeh M, Rahimi H, Rahimi‐Movaghar A. Tramadol use and public health consequences in Iran: a systematic review and meta‐analysis. Addiction 2020, 115: 2213-2242. PMID: 32196801, DOI: 10.1111/add.15059.Peer-Reviewed Original ResearchConceptsPooled estimatesSystematic reviewConsistent with Preferred Reporting ItemsPrevalence of non-prescribed useIranian general populationPreferred Reporting ItemsPublic health challengeSystematically review studiesRandom-effects modelPrevalence of tramadol useMisuse of tramadolPublic health consequencesReporting ItemsHealth challengesPrescription analgesicsGeneral populationHealth consequencesHeterogeneous reportingFemale university studentsTramadol-related deathsMeta-analysisTramadol useSubgroups of malesNon-prescribed usePooled percentage